AstraZeneca PLC’s PI3Kα inhibitor Truqap (capivasertib) won US Food and Drug Administration approval late last year and has quickly become the standard of care in certain patients with breast cancer, but could soon face a challenger in the form of Relay Therapeutics, Inc.’s RLY-2608, which has shown strong results in a Phase I clinical trial.
Cambridge, MA-based Relay announced interim results on 9 September from the study of RLY-2608 – an allosteric, pan-mutant and isoform-selective...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?